Cargando…

KAT8/MOF-Mediated Anti-Cancer Mechanism of Gemcitabine in Human Bladder Cancer Cells

Histone acetylation is a well-characterized epigenetic modification controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs). Imbalanced histone acetylation has been observed in many primary cancers. Therefore, efforts have been made to find drugs or small molecules such as H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Huihui, Wang, Yong, Wei, Tao, Zhao, Xiaoming, Li, Fuqiang, Li, Yana, Wang, Fei, Cai, Yong, Jin, Jingji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Applied Pharmacology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921864/ https://www.ncbi.nlm.nih.gov/pubmed/33041265 http://dx.doi.org/10.4062/biomolther.2020.111

Ejemplares similares

The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis
por: Su, Jiaming, et al.
Publicado: (2016)

The Males Absent on the First (MOF) Mediated Acetylation Alters the Protein Stability and Transcriptional Activity of YY1 in HCT116 Cells
por: Wu, Tingting, et al.
Publicado: (2023)

Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy
por: Zhu, Huihui, et al.
Publicado: (2020)

MiR-372-3p Functions as a Tumor Suppressor in Colon Cancer by Targeting MAP3K2
por: Li, Yana, et al.
Publicado: (2022)

KATs in Cancer: Functions and Therapies
por: Farria, Aimee, et al.
Publicado: (2015)

O-GlcNAc-Modification of NSL3 at Thr755 Site Maintains the Holoenzyme Activity of MOF/NSL Histone Acetyltransferase Complex
por: Zhao, Linhong, et al.
Publicado: (2019)

Arsenic Trioxide Reduces Global Histone H4 Acetylation at Lysine 16 through Direct Binding to Histone Acetyltransferase hMOF in Human Cells
por: Liu, Da, et al.
Publicado: (2015)

KAT8 acetylation-controlled lipolysis affects the invasive and migratory potential of colorectal cancer cells
por: Qiu, Bingquan, et al.
Publicado: (2023)

Sunitinib Malate Synergistically Potentiates Anti-Tumor Effect of Gemcitabine in Human Bladder Cancer Cells
por: Yoon, Cheol Yong, et al.
Publicado: (2011)

YY1/BCCIP Coordinately Regulates P53-Responsive Element (p53RE)-Mediated Transactivation of p21(Waf1/Cip1)
por: Sui, Yi, et al.
Publicado: (2019)

Substrate Scope for Human Histone Lysine Acetyltransferase KAT8
por: Proietti, Giordano, et al.
Publicado: (2021)

KAT8 selectively inhibits antiviral immunity by acetylating IRF3
por: Huai, Wanwan, et al.
Publicado: (2019)

New KAT6 inhibitors induce senescence and arrest cancer growth
por: Huang, Fei
Publicado: (2018)

Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence
por: Wang, Tian-Wei, et al.
Publicado: (2019)

Correction: KAT8 selectively inhibits antiviral immunity by acetylating IRF3
por: Huai, Wanwan, et al.
Publicado: (2019)

Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer
por: Tomko, Andrea M., et al.
Publicado: (2022)

Knockdown of KAT5/KIF11 induces autophagy and promotes apoptosis in anaplastic thyroid cancer cells
por: Fu, Lei, et al.
Publicado: (2023)

First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8
por: Fiorentino, Francesco, et al.
Publicado: (2023)

Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment
por: Song, Yuxuan, et al.
Publicado: (2022)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells
por: Dong, Zhen, et al.
Publicado: (2019)

M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine
por: Tang, Zhiling, et al.
Publicado: (2022)

Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance
por: He, Yan, et al.
Publicado: (2023)

Development of the Cu/ZIF-8 MOF Acid-Sensitive Nanocatalytic Platform Capable of Chemo/Chemodynamic Therapy with Improved Anti-Tumor Efficacy
por: Liang, Jie, et al.
Publicado: (2023)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

KAT5 histone acetyltransferase mutations in cancer cells
por: L Hardison, Kimberly, et al.
Publicado: (2022)

HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation
por: Yin, Hubin, et al.
Publicado: (2017)

Maternal histone acetyltransferase KAT8 is required for porcine preimplantation embryo development
por: Cao, Zubing, et al.
Publicado: (2017)

Bioinformatics analysis of prognosis and immune microenvironment of immunological cell death-related gemcitabine-resistance genes in bladder cancer
por: Liu, Chao, et al.
Publicado: (2022)

The Non-Specific Lethal (NSL) Histone Acetyltransferase Complex Transcriptionally Regulates Yin Yang 1-Mediated Cell Proliferation in Human Cells
por: Liu, Hongsen, et al.
Publicado: (2022)

Antiproliferative and apoptotic activity of gemcitabine-lauric acid conjugate on human bladder cancer cells
por: Wang, Hongxia, et al.
Publicado: (2022)

A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer
por: Sun, Liang, et al.
Publicado: (2015)

Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate
por: Xiang, Wei, et al.
Publicado: (2022)

Targeting cancer using KAT inhibitors to mimic lethal knockouts
por: Brown, James A.L., et al.
Publicado: (2016)

Quantifying Tip60 (Kat5) stratifies breast cancer
por: McGuire, A., et al.
Publicado: (2019)

Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
por: Wu, Ying-Si, et al.
Publicado: (2021)

Identification of acetyltransferase genes (HAT1 and KAT8) regulating HBV replication by RNAi screening
por: Wang, Hui, et al.
Publicado: (2015)

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
por: Narayan, Vivek, et al.
Publicado: (2016)

BioMOF-Based Anti-Cancer Drug Delivery Systems
por: Elmehrath, Sandy, et al.
Publicado: (2023)

Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder
por: Wang, Xiaoming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fm2245uqid2k53nsve2p4eq7ro